M. Mark

发表

Quality of life and pain in patients with metastatic bone disease from solid tumors treated with bone-targeted agents– a real-world cross-sectional study from Switzerland (SAKK 95/16)

B. Thürlimann, R. Cathomas, P. Bohanes, 2021, BMC cancer.

Vitamin D levels in Swiss breast cancer survivors.

B. Thürlimann, T. Ruhstaller, W. Riesen, 2018, Swiss medical weekly.

Time trends in avoidable cancer mortality in Switzerland and neighbouring European countries 1996-2010.

K. Clough-Gorr, A. Feller, M. Mark, 2015, Swiss medical weekly.

Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study

G. Ceresoli, A. Maconi, F. Grosso, 2022, ESMO open.

Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non–Small Cell Lung Cancer Failing First‐Line Platinum‐Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS‐lung Trial

H. Groen, V. Torri, U. Dafni, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial

N. Reinmuth, U. Dafni, R. Stahel, 2020 .

Progressive brain metastases in an EGFR mutated adenocarcinoma of the lung: Response to gefitinib after progression on erlotinib

R. Cathomas, M. Früh, M. Mark, 2014 .

SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2

A. Addeo, M. Joerger, S. Rothschild, 2020, Cancer Immunology, Immunotherapy.

Patterns of care for patients with metastatic bone disease in solid tumors: A cross-sectional study from Switzerland (SAKK 95/16)

B. Thürlimann, R. Cathomas, P. Bohanes, 2019, Journal of bone oncology.

Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland - the SAKK 95/16 prostate study.

B. Thürlimann, R. Cathomas, M. Schwenkglenks, 2021, Swiss medical weekly.

Combination of cisplatin and lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma: Report of two cases.

R. Cathomas, Y. Metaxas, M. Mark, 2016, Lung cancer.

1237MO SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA (N2) non-small cell lung cancer (NSCLC) – A multicenter single-arm phase II trial

C. Britschgi, D. Betticher, M. Joerger, 2020 .

Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16).

G. Ceresoli, A. Maconi, F. Grosso, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of Addition of Metformin to Abiraterone in Metastatic Castration‐Resistant Prostate Cancer Patients With Disease Progressing While Receiving Abiraterone Treatment (MetAb‐Pro): Phase 2 Pilot Study

R. Winterhalder, M. Pollak, R. Cathomas, 2019, Clinical genitourinary cancer.

SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non–Small-Cell Lung Cancer—A Multicenter Single-Arm Phase II Trial

S. Peters, C. Britschgi, D. Betticher, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small Cell Lung Cancer — A Multicentre Single-Arm Phase II Trial

S. Peters, C. Britschgi, D. Betticher, 2021 .

Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long‐Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01)

R. Mirimanoff, R. Stupp, R. Stahel, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Orteronel Switch Maintenance Therapy in Metastatic Castration Resistant Prostate Cancer After First‐Line Docetaxel: A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial (SAKK 08/11)

J. Bernhard, R. Winterhalder, S. Crabb, 2016, The Prostate.

Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors

A. Stathis, M. Joerger, C. Catapano, 2017, Investigational New Drugs.

Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial.

C. Sessa, S. Rothschild, I. Colombo, 2021, Lung cancer.

P76.03 Efficacy and Safety of Capmatinib Plus Nivolumab in Pretreated Patients with EGFR Wild-Type Non–Small Cell Lung Cancer

Ying Cheng, E. Felip, J. Wolf, 2021 .

Clinical Outcome of ALK‐Positive Non–Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co‐Mutations Receiving Tyrosine Kinase Inhibitors (TKIs)

W. Jochum, J. Diebold, S. Rothschild, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[Treatment of metastatic melanoma: are we entering the era of targeted treatment?].

R. Cathomas, F. Hitz, M. Mark, 2012, Praxis.

Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study.

A. Addeo, B. Calgua, M. Joerger, 2021, Lung cancer.

Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials

R. Stupp, A. Addeo, D. Betticher, 2022, ESMO open.

Weekly carboplatin in combination with weekly paclitaxel in the treatment of metastatic non-small cell lung cancer: a single center 10-year experience

P. Brossart, R. Cathomas, D. Klingbiel, 2016, Supportive Care in Cancer.

IMPACT OF EARLY PROPHYLACTIC CRANIAL IRRADIATION WITH HIPPOCAMPAL AVOIDANCE ON NEUROCOGNITIVE FUNCTION IN PATIENTS WITH LIMITED DISEASE SMALL-CELL LUNG CANCER. A MULTICENTER PHASE II TRIAL (SAKK 15/12).

C. B. Rudolf, A. Allal, D. Aebersold, 2020, International journal of radiation oncology, biology, physics.

Impact of early prophylactic cranial irradiation with hippocampal avoidance on neurocognitive function in patients with limited disease small cell lung cancer: A multicenter phase II trial (SAKK 15/12).

D. Betticher, D. Aebersold, F. Caparrotti, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)—A multicenter single-arm phase II trial.

S. Peters, C. Britschgi, D. Betticher, 2016 .

A randomised open-label phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC - the ETOP and EORTC SPLENDOUR trial.

N. Reinmuth, U. Dafni, R. Stahel, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Lung cancer screening: current evidence and recommendations

M. Brutsche, O. Gautschi, M. Mark, 2012, memo - Magazine of European Medical Oncology.

A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors

H. Lane, A. Stathis, C. Sessa, 2019, Investigational New Drugs.

Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14

R. Stupp, A. Addeo, D. Betticher, 2023, ESMO open.

Fatal pneumonitis after treatment with pegylated liposomal doxorubicin in a patient with metastatic breast cancer in complete remission

B. Thürlimann, M. Mark, 2012, Medical Oncology.

Cross-sectional study of self-reported physical activity, eating habits and use of complementary medicine in breast cancer survivors

B. Thürlimann, T. Ruhstaller, D. Dietrich, 2013, BMC Cancer.

A randomised phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC: The ETOP and EORTC SPLENDOUR trial.

N. Reinmuth, U. Dafni, R. Stahel, 2018, Annals of Oncology.

Vitamin D levels in Swiss breast cancer survivors.

B. Thürlimann, T. Ruhstaller, W. Riesen, 2018, Swiss medical weekly.

Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study.

A. Addeo, B. Calgua, M. Joerger, 2022, Lung cancer.